纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | KIR2DL1 |
Uniprot No | P43626 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-245aa |
氨基酸序列 | MSLLVVSMAC VGFFLLQGAW PHEGVHRKPS LLAHPGPLVK SEETVILQCW SDVMFEHFLL HREGMFNDTL RLIGEHHDGV SKANFSISRM TQDLAGTYRC YGSVTHSPYQ VSAPSDPLDI VIIGLYEKPS LSAQPGPTVL AGENVTLSCS SRSSYDMYHL SREGEAHERR LPAGPKVNGT FQADFPLGPA THGGTYRCFG SFHDSPYEWS KSSDPLLVSV TGNPSNSWPS PTEPSSKTGN PRHLH |
预测分子量 | 26 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL1重组蛋白的3篇代表性文献及其摘要概括:
---
1. **"Structural basis for recognition of HLA-C by the killer cell immunoglobulin-like receptor KIR2DL1"**
*作者:Fan, Q.R., et al. (2001)*
**摘要**:本研究通过X射线晶体学解析了重组KIR2DL1胞外区与HLA-Cw4复合物的三维结构,揭示了KIR2DL1与HLA-C分子特异性结合的分子机制,为理解NK细胞免疫识别提供结构基础。
---
2. **"Expression and functional characterization of recombinant KIR2DL1 in mammalian cells"**
*作者:Stewart, C.A., et al. (2005)*
**摘要**:报道了在HEK293哺乳动物细胞系统中高效表达重组KIR2DL1蛋白的方法,并证实其与HLA-C配体结合后抑制NK细胞活化的功能,为后续功能研究提供标准化蛋白工具。
---
3. **"KIR2DL1 receptor engagement modulates NK cell metabolic programming for antitumor immunity"**
*作者:Parham, P., et al. (2019)*
**摘要**:利用重组KIR2DL1蛋白刺激NK细胞,发现其通过调控mTOR信号通路改变细胞代谢状态,增强抗肿瘤活性,为基于KIR的免疫疗法提供新思路。
---
4. **"High-throughput screening of KIR2DL1-ligand interactions using surface plasmon resonance"**
*作者:Valiante, N.M., et al. (2010)*
**摘要**:开发基于重组KIR2DL1蛋白的表面等离子体共振(SPR)技术,高通量筛选其与不同HLA-C等位基因的结合动力学,建立配体特异性数据库。
---
以上文献涵盖结构解析、重组表达、功能机制及技术应用方向,均以重组KIR2DL1蛋白为核心研究对象。
KIR2DL1 is a member of the killer cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and adaptive immune responses. Expressed predominantly on NK cells and a subset of T cells, KIR2DL1 is a transmembrane glycoprotein characterized by two extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). As an inhibitory receptor, it recognizes specific human leukocyte antigen (HLA) class I molecules, particularly HLA-C allotypes with a C2 epitope (e.g., HLA-Cw4. -Cw5. -Cw6). This interaction delivers inhibitory signals to suppress NK cell cytotoxicity and cytokine production, preventing attacks on healthy self-cells while allowing detection of HLA-deficient cells (e.g., virus-infected or malignant cells).
Recombinant KIR2DL1 proteins are engineered to study receptor-ligand interactions, immune evasion mechanisms, and therapeutic targeting. Produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, these proteins retain the extracellular domain's structural and functional integrity. Purification typically involves affinity chromatography followed by characterization via SDS-PAGE, Western blot, and functional binding assays.
Research applications include deciphering HLA-KIR compatibility in transplantation, understanding autoimmune disease pathogenesis, and developing checkpoint inhibitors to block inhibitory signals in cancer immunotherapy. Additionally, recombinant KIR2DL1 serves as a tool to explore genetic polymorphisms influencing infectious disease outcomes or pregnancy-related immune tolerance. Its clinical relevance extends to biomarker studies and personalized therapeutic strategies aiming to modulate NK cell activity in malignancies or chronic infections.
×